Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the quarter and six month period ended June 30, 2008 and provided an update on the Company's progress with its product development candidates. The net loss for the quarter and six month period ended June 30, 2008, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $14.1 million and $28.7 million, respectively, compared to a net loss of $10.3 million and $21.2 million in the comparable periods in 2007. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at June 30, 2008 of $95.3 million.

"Alexza continues to make significant progress with our lead program, AZ-004 (Staccato(R) loxapine), which is being developed for the treatment of acute agitation in schizophrenic or bipolar disorder patients," said Thomas B. King, President and CEO of Alexza. "During the first seven months of 2008, we initiated and completed the dosing of our first AZ-004 Phase 3 clinical trial, and have initiated dosing of our second AZ-004 Phase 3 clinical trial. In addition, we had clinical readouts from clinical trials with AZ-104, AZ-007 and AZ-002. We are also scaling up our manufacturing, quality systems, regulatory affairs and commercial operations as we prepare for the future commercialization of AZ-004."

Financial Results - Periods Ended June 30, 2008 and 2007

GAAP operating expenses were $20.5 million and $39.7 million in the quarter and six month period ended June 30, 2008, compared to $14.2 million and $28.0 million for the comparable periods in 2007. The increases resulted primaril
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)...  Eli Lilly and Company (NYSE: LLY ) ... Thursday, September 17, 2015. Sue Mahony , Ph.D., ... Richard Gaynor , M.D., senior vice president of ... participate in a fireside chat at 3:30 p.m., Eastern ... will be available on the "Webcasts & Presentations" section ...
(Date:8/27/2015)... , Aug. 27, 2015  A mere one in ... Booz Allen Hamilton . A new white paper ... inefficiencies are impeding and disrupting manufacturers, success. ... and Improve Value In Product Development Processes provides ... data and how it affects the product development process ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... 2011 Noverca – the first and currently only Italian ... its presence in the Health and Wellness Sector . ... treatment has been developed and launched thanks to the long-term ... N o verca) and Fatebenefratelli Hospital. ...
... SPRING, Md., April 8, 2011 The U.S. Food ... respirator, a device that kills 99.99 percent of three ... surface. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... as a single-use, N95 surgical respirator for use in ...
Cached Medicine Technology:EXTENDED HEALTH: Noverca Enters the World of Healthcare 2FDA Clears Single-Use Antibacterial Surgical Respirator 2
(Date:8/28/2015)... ... August 28, 2015 , ... ... accreditation for its adolescent residential, counseling, day treatment and intensive family based services. ... international standards for quality and its pursuit of excellence. As a nonprofit charity ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and Dr. ... $199, patients can currently receive a one hour treatment of this teeth whitening option. ... includes a number of unique features that can turn teeth up to nine shades ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... which is dedicated to distributing health information technology innovation to transform quality and ... Results of the survey will be de-identified and aggregated before being publicly shared ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... of the top 5 millionaire dating sites . According to the listings, ... the second best in this category. , A spokesperson of Top5MillionaireDatingSites.com ...
(Date:8/28/2015)... ... 28, 2015 , ... A complimentary webinar offered by healthcare consulting and accounting ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement ... Comprehensive Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September ...
Breaking Medicine News(10 mins):Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3
... proper placement and anchor ... ... ; LSE: SN) Endoscopy Division today announced the launch of the,BIORAPTOR 2.3 ... The device is featured at Smith & Nephew Endoscopy,s booth,at the American ...
... today proclaimed March 10-14 as Older Pennsylvanians, Nutrition,Awareness Week ... simple,dietary changes can help to improve their health and ... factor in staying healthy, and that,s,especially true for older ... for the percentage of seniors and their care and ...
... Chartis Group, a leading,healthcare advisory services firm, announced ... Karpook and Gregory Maddrey to the position of,Principal. ... advancing their strategic, organizational and operational,performance., "Each ... our clients and our,firm. Greg, James, Matt and ...
... Wounded in Recent Teen and School Shootings, ... gunman Steven Kazmierczak became the 12th shooter in ... documented by international,drug regulatory agencies to cause suicide, ... one antidepressant, "homicidal,ideation." With casualties from school or ...
... Md., March 5 On Saturday, March,29 at 8:00 ... 5K Run/Walk at,Quiet Waters Park in Annapolis to raise ... $20, runners will experience a beautiful 5K,waterfront course complete ... fastest runners. All proceeds from the event go toward ...
... in Your Teeth, VOORHEES, N.J., March 5 ... similar for 2007. Together with the,government,s economic stimulus tax ... pockets of most taxpayers this Spring, it,s a potential,windfall ... But rather than getting away for a week, you ...
Cached Medicine News:Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 4Health News:Governor Rendell Proclaims Older Pennsylvanians' Nutrition Awareness Week 2Health News:Governor Rendell Proclaims Older Pennsylvanians' Nutrition Awareness Week 3Health News:The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal 2Health News:The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal 3Health News:New Mini-Documentary Exposes Psychiatric Drugs Turning Kids into Killers 2Health News:New Mini-Documentary Exposes Psychiatric Drugs Turning Kids into Killers 3Health News:Inaugural Bowen Foundation Run/Walk to Fight Autism in Maryland Set for Saturday, March 29 2Health News:Smile When You Get that Refund 2
... screening of factor-V-related APC resistance. The high ... the factor V:Q506 mutation is obtained by ... of V-DEF Plasma bioreagent. The test design ... and homozygous factor V genotypes. It also ...
Inquire...
Inquire...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: